Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics for potential consideration of up to $7 billion. This acquisition marks Lilly’s strategic entry into the cell therapy space, specifically targeting the cost and logistical barriers associated with traditional CAR-T treatments.
Deal specifics
-
Payment structure: Lilly will pay $3.25 billion upfront, with up to $3.75 billion in additional milestone payments linked to clinical, regulatory, and commercial achievements.
-
Expected closing: The transaction is anticipated to close in the second half of 2026, subject to customary regulatory approvals.
-
Context: This follows other major oncology-focused moves by Lilly, including the acquisition of Centessa Pharmaceuticals ($7.8 billion).
The iGPS technological breakthrough The core value of Kelonia lies in its proprietary iGPS (in vivo Gene Placement System), which represents a paradigm shift from current CAR-T methodologies:
-
Current process (ex vivo): Requires extracting a patient’s T-cells, genetically engineering them in a specialized facility over several weeks, and reinfusing them—a process that is time-consuming, expensive, and limited in scale.
-
iGPS technology (in vivo): Uses engineered lentiviral particles delivered via a simple intravenous injection. These particles selectively enter T-cells inside the patient’s body, directing them to express CARs without the cells ever leaving the patient.
Clinical and strategic importance Kelonia’s lead program, KLN-1010, is an anti-BCMA therapy targeting multiple myeloma. Early Phase I clinical data presented in 2025 demonstrated promising tolerability and provided initial proof-of-concept for the “off-the-shelf” in vivo platform.
For Eli Lilly, this acquisition provides a foothold in cell therapy and positions the company at the frontier of a platform shift. If successful, iGPS could transform CAR-T from a complex manufacturing-heavy procedure into a simplified, widely accessible treatment for a broader range of cancers and serious diseases.
Source: https://www.pharmexec.com/view/eli-lilly-enters-7-billion-agreement-acquire-kelonia-therapeutics